Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

REC-4881

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Recursion Pharma, Takeda

Drug class:

MEK1 inhibitor, MEK2 inhibitor

Related drugs:

BRAF L597S	Melanoma	BRAF L597S	Melanoma	REC-4881 Sensitive: C4 – Case Studies REC-4881 Sensitive : C4	REC-4881 Sensitive: C4 – Case Studies REC-4881 Sensitive : C4
GNA11 Q209L	Uveal Melanoma	GNA11 Q209L	Uveal Melanoma	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D
GNAQ Q209P	Uveal Melanoma	GNAQ Q209P	Uveal Melanoma	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D
EGFR wild-type	Lung Adenocarcinoma	EGFR wild-type	Lung Adenocarcinoma	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D